• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

    1.790 +0.060 (+3.47%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 874,714
    Open 1.740
    Bid (Size) 1.730 (1,000)
    Ask (Size) 1.850 (600)
    Prev. Close 1.730
    Today's Range 1.740 - 1.800
    52wk Range 0.7100 - 2.616
    Shares Outstanding 116,236,018
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    Coherus Oncology Inc (NASDAQ:CHRS) Reports Mixed Q4 2025 Results as LOQTORZI Sales Grow ↗
    Via Chartmill

    Performance

    YTD
    +30.7%
    +30.7%
    1 Month
    +3.5%
    +3.5%
    3 Month
    -17.5%
    -17.5%
    6 Month
    +11.9%
    +11.9%
    1 Year
    +62.7%
    +62.7%

    More News

    Read More
    News headline image
    Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology to Participate in Upcoming Investor Conferences
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Coherus BioSciences's Earnings Outlook ↗
    Via Benzinga
    News headline image
    Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    What's going on in today's session ↗
    Via Chartmill
    Which stocks are moving on Friday? ↗
    Via Chartmill
    The market is filled with gapping stocks in Friday's session. ↗
    Via Chartmill
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology to Participate in Upcoming Investor Conferences
    From Coherus Oncology, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Coherus Oncology, Inc. - Common Stock publicly traded?
    Yes, Coherus Oncology, Inc. - Common Stock is publicly traded.
    What exchange does Coherus Oncology, Inc. - Common Stock trade on?
    Coherus Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Coherus Oncology, Inc. - Common Stock?
    The ticker symbol for Coherus Oncology, Inc. - Common Stock is CHRS on the Nasdaq Stock Market
    What is the current price of Coherus Oncology, Inc. - Common Stock?
    The current price of Coherus Oncology, Inc. - Common Stock is 1.790
    When was Coherus Oncology, Inc. - Common Stock last traded?
    The last trade of Coherus Oncology, Inc. - Common Stock was at 05/05/26 04:00 PM ET
    What is the market capitalization of Coherus Oncology, Inc. - Common Stock?
    The market capitalization of Coherus Oncology, Inc. - Common Stock is 208.06M
    How many shares of Coherus Oncology, Inc. - Common Stock are outstanding?
    Coherus Oncology, Inc. - Common Stock has 208M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.